Fenretinide oral - Laurent Pharmaceuticals/McGill University
Alternative Names: Fenretinide oral - Laurent Pharmaceuticals; LAU-7bLatest Information Update: 08 Aug 2024
At a glance
- Originator Ortho-McNeil Pharmaceutical
- Developer Cystic Fibrosis Foundation Therapeutics; Laurent Pharmaceuticals; McGill University
- Class Antifibrotics; Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
- Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Cystic fibrosis
- Preclinical Pulmonary fibrosis
- No development reported Pseudomonal infections
Most Recent Events
- 30 May 2024 Laurent Pharmaceuticals completes the phase II RESOLUTION clinical trials in COVID-2019 infections (Adjunctive treatment) in Canada and USA (PO) (NCT04417257)
- 17 May 2024 Preclinical trials in Pulmonary fibrosis in Canada (PO) prior to May 2024
- 17 May 2024 Pharmacodynamics data from preclinical studies in Pulmonary fibrosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)